We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Arbutus Biopharma Corporation | NASDAQ:ABUS | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 2.81 | 2.75 | 2.94 | 11 | 12:00:06 |
Presentations Include:
Oral Presentation: “Controlling HBsAg as a Key Component of a Combination Strategy to Affect an HBV Cure” by Michael J. Sofia, Chief Scientific Officer
Oral and Poster Presentation #8: “A Next Generation HBV Capsid Inhibitor, AB-506: In Vitro and In Vivo Antiviral Characterization” by Nagraj Mani, Senior Principal Scientist
These presentations will be available by visiting the Investor section of www.arbutusbio.com and selecting Events and Presentations.
About Arbutus
Arbutus Biopharma Corporation is a biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic HBV infection. Arbutus is headquartered in Vancouver, BC, and has facilities in Warminster, PA. For more information, visit www.arbutusbio.com.
Contact Information
InvestorsBruce CousinsExecutive Vice President and Chief Financial OfficerPhone: 604-419-3200Email: bcousins@arbutusbio.com
Tiffany TolmieManager, Investor RelationsPhone: 604-419-3200 Email: ttolmie@arbutusbio.com
MediaDavid SchullRusso PartnersPhone: 858-717-2310Email: david.schull@russopartnersllc.com
1 Year Arbutus Biopharma Chart |
1 Month Arbutus Biopharma Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions